{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:03:34Z","timestamp":1791169414451,"version":"4.1.0"},"reference-count":181,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.critrevonc.2014.11.001","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T01:23:29Z","timestamp":1416187409000},"page":"277-292","source":"Crossref","is-referenced-by-count":89,"title":["Mechanisms of resistance to BCR\u2013ABL TKIs and the therapeutic strategies: A review"],"prefix":"10.1016","volume":"93","author":[{"given":"Ke","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-wu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2014.11.001_bib0005","first-page":"104","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"51","author":"Rowley","year":"2004"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13238-010-0016-z","article-title":"Molecular and cellular bases of chronic myeloid leukemia","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.2014.850491","article-title":"Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?","volume":"15","author":"Visani","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0025","first-page":"117","article-title":"Structure of the Bcr\u2013Abl oncoprotein oligomerization domain","volume":"9","author":"Zhao","year":"2002","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1947601912458584","article-title":"Structure, regulation, signaling, and targeting of abl kinases in cancer","volume":"3","author":"Hantschel","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0035","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-06-4312","article-title":"BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia","volume":"67","author":"Chu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0040","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0045","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1038\/sj.onc.1206008","article-title":"Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr\u2013Abl signal transduction and oncogenesis","volume":"21","author":"Wilson","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ardp.19963290707","article-title":"Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)","volume":"329","author":"Zimmermann","year":"1996","journal-title":"Arch Pharm (Weinheim)"},{"issue":"6263","key":"10.1016\/j.critrevonc.2014.11.001_bib0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2014.11.001_bib0065","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80599-8","article-title":"Imatinib: a selective tyrosine kinase inhibitor","volume":"38","author":"Manley","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0070","doi-asserted-by":"crossref","first-page":"11410","DOI":"10.1073\/pnas.96.20.11410","article-title":"Platelet-derived growth factor \u03b2 receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3\u2032 kinase signaling","volume":"96","author":"Heuchel","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0075","first-page":"2929","article-title":"Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors","volume":"61","author":"Pietras","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0080","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0085","first-page":"8118","article-title":"KIT activation is a ubiquitous feature of gastrointestinal stromal tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.11.001_bib0090","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ctrv.2013.07.005","article-title":"Adherence to imatinib therapy in patients with gastrointestinal stromal tumors","volume":"40","author":"Blay","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/rheumatology\/ken431","article-title":"Imatinib as a novel therapeutic approach for fibrotic disorders","volume":"48","author":"Distler","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0105","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0110","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","article-title":"Roots of clinical resistance to STI-571 cancer therapy","volume":"293","author":"Barthe","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0115","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2014.11.001_bib0120","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.leukres.2013.06.014","article-title":"XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells","volume":"37","author":"Silva","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0125","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome\u2013positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.305.5682.319a","article-title":"Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance","volume":"305","author":"Travis","year":"2004","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.critrevonc.2014.11.001_bib0135","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2012-11-466425","article-title":"The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cell by chemotherapeutic agents","volume":"122","author":"Dos Santos","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.11.001_bib0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2013.06.041","article-title":"Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells","volume":"185","author":"Kim","year":"2013","journal-title":"J Surg Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-013-2166-1","article-title":"Synergistic antitumor effects of Dasatinib and oxaliplatin in gastric cancer cells","volume":"72","author":"Shi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.11.001_bib0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.lungcan.2013.07.004","article-title":"Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia","volume":"82","author":"Pitini","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1593\/tlo.13259","article-title":"Dasatinib inhibits DNA repair after radiotherapy specifically in pSFK-expressing tumor areas in head and neck xenograft tumors","volume":"6","author":"Stegeman","year":"2013","journal-title":"Transl Oncol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0160","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.3892\/or.2013.2405","article-title":"Enhanced antitumor activity by the combination of dasatinib and combretastatin A-4 in vitro and in vivo","volume":"29","author":"Zhang","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/leu.2009.267","article-title":"Dasatinib promotes ATRA-induced differentiation of AML cells","volume":"24","author":"Kropf","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0170","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/leu.2011.390","article-title":"Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells","volume":"26","author":"Congleton","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0175","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.bcp.2011.05.011","article-title":"Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action","volume":"82","author":"Lainey","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0180","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2010.151","article-title":"Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib","volume":"24","author":"Chevalier","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0185","doi-asserted-by":"crossref","first-page":"e66915","DOI":"10.1371\/journal.pone.0066915","article-title":"MEK\/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia","volume":"8","author":"Fang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0190","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0200","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2007-08-105858","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy (vol 109, pg 2303, 2007)","volume":"110","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0205","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0210","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1158\/1078-0432.CCR-13-0980","article-title":"Contribution of abcc4-mediated gastric transport to the absorption and efficacy of dasatinib","volume":"19","author":"Furmanski","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0215","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR\u2013ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0220","first-page":"218","article-title":"Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene","volume":"35","author":"Bellesso","year":"2013","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0225","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamadermatol.2013.75","article-title":"Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia","volume":"149","author":"Samimi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr\u2013Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0235","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr\u2013Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2014.11.001_bib0240","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0245","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nrclinonc.2013.51","article-title":"Haematological cancer: Nilotinib reduces emergence of BCR\u2013ABL mutations in CML","volume":"10","author":"Marchesi","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0250","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","article-title":"Bcr\u2013Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the AN kinase inhibitor nilotinib (AMN107)","volume":"108","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0255","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr\u2013Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0260","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR\u2013ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0265","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.bbamcr.2013.02.033","article-title":"Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases","volume":"1833","author":"Shaker","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0270","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","article-title":"Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"Coutre","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0275","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1345\/aph.1R334","article-title":"Nilotinib-associated acute pancreatitis","volume":"47","author":"Engel","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0280","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quintas-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0285","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12185-012-1103-0","article-title":"Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia","volume":"96","author":"Zakrzewski","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0290","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-012-1026-9","article-title":"Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or-intolerant Ph plus CML or relapsed\/refractory Ph+ ALL: a 36-month analysis of a phase I and II study","volume":"95","author":"Usuki","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0295","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","article-title":"A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed\/refractory Ph plus ALL","volume":"89","author":"Tojo","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0300","doi-asserted-by":"crossref","first-page":"528a","DOI":"10.1182\/blood.V108.11.1862.1862","article-title":"A phase II study of nilotinib, a novel tyrosine vinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory Ph plus acute lymphoblastic leukemia (ALL)","volume":"108","author":"Ottmann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0305","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0310","doi-asserted-by":"crossref","unstructured":"pan-BCR\u2013ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401\u2013412.","DOI":"10.1016\/j.ccr.2009.09.028"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.11.001_bib0315","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome\u2013positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0320","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4161\/cc.24982","article-title":"Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines","volume":"12","author":"Dufies","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0325","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbrc.2013.05.022","article-title":"Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells","volume":"435","author":"Okabe","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0330","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","article-title":"Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies","volume":"10","author":"Gozgit","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0335","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2141.2012.09085.x","article-title":"Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation","volume":"157","author":"Zirm","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0340","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2012.066407","article-title":"Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0345","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00280-013-2131-z","article-title":"Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models","volume":"71","author":"Gozgit","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0350","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0355","doi-asserted-by":"crossref","first-page":"20214","DOI":"10.1021\/ja310659j","article-title":"Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors","volume":"134","author":"Gushwa","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0360","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3892\/or.2013.2386","article-title":"Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1","volume":"29","author":"Ren","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0365","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1593\/neo.121106","article-title":"The N550K\/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors","volume":"15","author":"Byron","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0370","doi-asserted-by":"crossref","first-page":"E811","DOI":"10.1210\/jc.2012-2672","article-title":"Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer","volume":"98","author":"De Falco","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0925","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr\u2013Abl(+) neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0380","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrclinonc.2012.226","article-title":"Haematology: Ponatinib\u2014the next TKI challenge","volume":"10","author":"Razzak","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0390","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr\u2013Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0395","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0400","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0410","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.ejca.2010.02.032","article-title":"Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia","volume":"46","author":"Boschelli","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0415","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0420","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/724360","article-title":"Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells","author":"Hamad","year":"2013","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0425","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0430","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The Biology of CML blast crisis","author":"Radich","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0435","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","article-title":"Genetic mechanisms of chronic myeloid leukemia blastic transformation","volume":"7","author":"Skorski","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"18","key":"10.1016\/j.critrevonc.2014.11.001_bib0440","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0445","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR\u2013ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0450","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR\u2013ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0455","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR\u2013ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0460","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2011.08.009","article-title":"Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients","volume":"312","author":"Tanaka","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0465","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0470","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0475","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte\u2013macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0480","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1134\/S0006297908010045","article-title":"Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2011","journal-title":"Biochemistry (Moscow)"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0485","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3324\/haematol.2009.008631","article-title":"ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug","volume":"94","author":"Chapuy","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0490","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood-2003-03-0993","article-title":"Functional consequence of MDR1 expression on imatinib intracellular concentrations","volume":"102","author":"Widmer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0495","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5732\/cjc.011.10327","article-title":"Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells","volume":"31","author":"Peng","year":"2012","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0500","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","article-title":"Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1","volume":"1587","author":"Heged\u0171s","year":"2002","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0505","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0510","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10915810600746023","article-title":"Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters","volume":"25","author":"Choudhuri","year":"2006","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0930","doi-asserted-by":"crossref","first-page":"46400","DOI":"10.1074\/jbc.M107041200","article-title":"Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3)","volume":"276","author":"Zelcer","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0520","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/mp2001022","article-title":"Synthesis and characterization of a BODIPY conjugate of the BCR\u2013ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters","volume":"8","author":"Shukla","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0525","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0530","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0535","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4161\/onci.20249","article-title":"Environment-mediated drug resistance in Bcr\/Abl-positive acute lymphoblastic leukemia","volume":"1","author":"Feldhahn","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0540","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ejca.2008.10.012","article-title":"Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells","volume":"45","author":"Naldini","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0545","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1749-6632.2000.tb06182.x","article-title":"Free radicals and antioxidants in the year 2000. A historical look to the future","volume":"899","author":"Gutteridge","year":"2000","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0550","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1097-2765(02)00513-0","article-title":"The yeast CDK inhibitor Sic1 prevents genomic instability by promoting replication origin licensing in late G(1)","volume":"9","author":"Lengronne","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0555","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/em.1070","article-title":"Complexities of the DNA base excision repair pathway for repair of oxidative DNA damage","volume":"38","author":"Mitra","year":"2001","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0560","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1073\/pnas.91.14.6609","article-title":"Reverse chemical mutagenesis: identification of the mutagenic lesions resulting from reactive oxygen species-mediated damage to DNA","volume":"91","author":"Feig","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0565","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0300-9084(99)80039-X","article-title":"Base excision repair of 8-hydroxyguanine protects DNA from endogenous oxidative stress","volume":"81","author":"Boiteux","year":"1999","journal-title":"Biochimie"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0570","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1098\/rstb.2008.0186","article-title":"Uracil in DNA and its processing by different DNA glycosylases","volume":"364","author":"Visnes","year":"2009","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0575","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2012.294","article-title":"BCR\u2013ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability","volume":"27","author":"Slupianek","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0580","doi-asserted-by":"crossref","first-page":"16348","DOI":"10.3390\/ijms140816348","article-title":"The role of mitochondrial DNA damage and repair in the resistance of BCR\/ABL-expressing cells to tyrosine kinase inhibitors","volume":"14","author":"Glowacki","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0585","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cell.2007.10.005","article-title":"A backup DNA repair pathway moves to the forefront","volume":"131","author":"Nussenzweig","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0590","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0595","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0600","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/MCB.22.12.4189-4201.2002","article-title":"Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2\/M phase, and protection from apoptosis","volume":"22","author":"Slupianek","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0605","first-page":"1798","article-title":"Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins","volume":"63","author":"Brady","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0610","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1038\/sj.onc.1206087","article-title":"BCR\/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability","volume":"21","author":"Skorski","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0615","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.1104904","article-title":"Endogenous MHC class II processing of a viral nuclear antigen after autophagy","volume":"307","author":"Paludan","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0620","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nature06268","article-title":"SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation","volume":"450","author":"Vaquero","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0625","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molcel.2011.02.034","article-title":"Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection","volume":"42","author":"Bosch-Presegue","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0630","doi-asserted-by":"crossref","first-page":"e1000155","DOI":"10.1371\/journal.pgen.1000155","article-title":"Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island","volume":"4","author":"O\u2019Hagan","year":"2008","journal-title":"PLoS Genet"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0635","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/onc.2012.83","article-title":"SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0640","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.dnarep.2005.10.005","article-title":"BCR\/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells","volume":"5","author":"Slupianek","year":"2006","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0645","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr\u2013Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0650","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/leu.2012.222","article-title":"Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr\u2013Abl inhibitors","volume":"27","author":"Wohrle","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0655","doi-asserted-by":"crossref","first-page":"e9152","DOI":"10.1371\/journal.pone.0009152","article-title":"Gab2 promotes hematopoietic stem cell maintenance and self-renewal synergistically with STAT5","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0660","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0609.2009.01387.x","article-title":"BCR\u2013ABL-independent and RAS\/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4","volume":"84","author":"Suzuki","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0665","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","article-title":"Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance","volume":"46","author":"McCubrey","year":"2006","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0670","first-page":"585","article-title":"BCR\u2013ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML","volume":"39","author":"Hentschel","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0675","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0680","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR\u2013ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0685","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00432-011-1086-x","article-title":"Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR\u2013ABL-expressing cells: a potential mechanism of altered leukemogenicity","volume":"138","author":"Hartel","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.critrevonc.2014.11.001_bib0690","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","article-title":"The chronic myeloid leukemia stem cell","volume":"9","author":"Nicholson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0695","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s13238-013-2115-0","article-title":"Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells","volume":"4","author":"Zhang","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0700","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","article-title":"The novel BCR\u2013ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2","volume":"11","author":"Sen","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0705","doi-asserted-by":"crossref","first-page":"e7520","DOI":"10.1371\/journal.pone.0007520","article-title":"Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10)","volume":"4","author":"Shen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0710","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/onc.2012.203","article-title":"Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias","volume":"32","author":"Tobin","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0715","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","article-title":"Activation of stress response gene SIRT1 by BCR\u2013ABL promotes leukemogenesis","volume":"119","author":"Yuan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0720","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0725","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","article-title":"Activation of stress response gene SIRT1 by BCR\u2013ABL promotes leukemogenesis","volume":"119","author":"Yuan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0730","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0735","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr\u2013Abl signaling in chronic myeloid leukemia","volume":"25","author":"Samanta","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0740","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","article-title":"Janus kinase 2: a critical target in chronic myelogenous leukemia","volume":"66","author":"Samanta","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0745","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0750","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbrc.2010.02.173","article-title":"Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis","volume":"396","author":"R\u00e5dmark","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0755","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0760","doi-asserted-by":"crossref","first-page":"724360","DOI":"10.1155\/2013\/724360","article-title":"Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells","volume":"2013","author":"Hamad","year":"2013","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0765","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0770","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0775","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR\u2013ABL-induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0780","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nrc1229","article-title":"Hedgehog signalling in cancer formation and maintenance","volume":"3","author":"Pasca di Magliano","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0785","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2011.143","article-title":"The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis","volume":"25","author":"Mar","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0790","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.4161\/cc.9.17.12945","article-title":"Hedgehog pathway activation in chronic myeloid leukemia: a promise for a novel combination therapeutic approach?","volume":"9","author":"Jagani","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0795","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr\u2013Abl-positive leukemic stem cells is dependent on hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0800","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.biopha.2011.12.008","article-title":"Sonic hedgehog signaling regulates Bcr\u2013Abl expression in human chronic myeloid leukemia cells","volume":"66","author":"Liao","year":"2012","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0805","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1467-7652.2009.00409.x","article-title":"Antioxidant and anti-inflammatory properties of tomato fruits synthesizing different amounts of stilbenes","volume":"7","author":"D\u2019Introno","year":"2009","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0815","first-page":"235","article-title":"Cyclin-dependent kinase inhibitors","volume":"5","author":"Fischer","year":"2003","journal-title":"Prog Cell Cycle Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0820","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1158\/1535-7163.MCT-05-0235","article-title":"Flavopiridol disrupts STAT3\/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy","volume":"5","author":"Lee","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0825","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4161\/cc.3.12.1278","article-title":"Flavopiridol, an inhibitor of transcription: implications, problems and solutions","volume":"3","author":"Blagosklonny","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0830","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-040020","article-title":"Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol","volume":"10","author":"Shapiro","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0835","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.7-suppl_3-12","article-title":"The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01","volume":"7","author":"Senderowicz","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0840","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00280-012-1839-5","article-title":"Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies","volume":"69","author":"Bose","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0845","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00280-012-1839-5","article-title":"Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies","volume":"69","author":"Bose","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0850","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","article-title":"Danusertib (formerly PHA-739358)\u2014a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor","volume":"184","author":"Gontarewicz","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0855","doi-asserted-by":"crossref","first-page":"10436","DOI":"10.1158\/0008-5472.CAN-07-1379","article-title":"Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells","volume":"67","author":"Guan","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0860","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/carcin\/bgn176","article-title":"Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells","volume":"29","author":"Wan","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0865","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.1158\/0008-5472.CAN-10-1246","article-title":"The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the cofilin-F-actin pathway","volume":"70","author":"Wang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0870","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.4161\/auto.22110","article-title":"Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells","volume":"8","author":"Zou","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0875","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1476-4598-8-95","article-title":"Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival","volume":"8","author":"Yao","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0880","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0885","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","article-title":"AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol","volume":"3","author":"Anand","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0890","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: potential efficacy of BCR\u2013ABL and autophagy inhibition in CML","volume":"118","author":"Helgason","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0895","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells","volume":"26","author":"Yu","year":"2012","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2014.11.001_bib0900","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/10428194.2010.546913","article-title":"Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors","volume":"52","author":"Calabretta","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0905","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome\u2013positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0910","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2014.11.001_bib0915","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.clml.2011.03.032","article-title":"Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation","volume":"11","author":"Cornelison","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.critrevonc.2014.11.001_bib0920","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-012-1005-1","article-title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa","volume":"95","author":"Itonaga","year":"2012","journal-title":"Int J Hematol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814001851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814001851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:53:54Z","timestamp":1747162434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842814001851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":181,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1040842814001851"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2014.11.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}